Deze website met internetadres http://www.pfizerpro.nl en alle hierop vermelde informatie is uitsluitend gericht op inwoners van Nederland.

Zoek

Menu

Close

Inloggen of registrerenUitloggenOnze geneesmiddelenZiektebeeldenOntdek meerOntdek meerEducatieMaterialenVideo'sPodcastOver PfizerOver PfizerNieuwsBlogsMedewerkers in beeldContactContactNeem gerust contact met ons opStel een vraagPfizer medische informatie

Onderaan de pagina kunt u bijwerkingen melden.

Home

Menu

Close

EfficacyEfficacy DataTrial DesignClinical RemissionEndoscopic ImprovementBio/JAKi Subgroups DataIsolated ProctitisSafetyAdverse eventsCardiac and ocular adverse eventsGetting StartedResourcesEventsMaterialsVideos
Endoscopic Improvement

ELEVATE UC 52

ELEVATE UC 12

Tab Number 3

Tab Number 4

Tab Number 5

A greater proportion of patients experienced endoscopic improvement with VELSIPITY vs placebo1

VELSIPITY reduced inflammation in the colon in ELEVATE UC 52, further demonstrating the effectiveness of treatment1

ReferencesEndoscopic improvement was defined as an endoscopy score (ES) ≤1 (excluding friability).1Mucosal healing

VELSIPITY demonstrated mucosal healing in patients living with UC

A greater proportion of patients experienced mucosal healing with VELSIPITY vs placebo in ELEVATE UC 521

 ReferencesMucosal healing was defined as an endoscopy score (ES) ≤1 (excluding friability) with histologic remission (Geboes Index score <2.0, indicating no neutrophils in the epithelial crypts or lamina propria, no increase in eosinophils, and no crypt destruction, erosions, ulcerations, or granulation tissue).1Efficacy in biologic/JAKi subgroupsSee how effective VELSIPITY was in  patients who were biologic/JAKi naive. EXPLORE SUBGROUPS LoadingReference:VELSIPITY (etrasimod) Summary of Product Characteristics. Brussels, Belgium: Pfizer Europe; February 2024.
A greater proportion of patients experienced endoscopic improvement with VELSIPITY vs placebo1

VELSIPITY reduced inflammation in the colon in ELEVATE UC 12, further demonstrating the effectiveness of treatment1

ReferencesEndoscopic improvement was defined as an endoscopy score (ES) ≤1 (excluding friability).1Mucosal healing

VELSIPITY demonstrated mucosal healing in patients living with UC

A greater proportion of patients experienced mucosal healing with VELSIPITY vs placebo in ELEVATE UC 121

 ReferencesMucosal healing was defined as an endoscopy score (ES) ≤1 (excluding friability) with histologic remission (Geboes Index score <2.0, indicating no neutrophils in the epithelial crypts or lamina propria, no increase in eosinophils, and no crypt destruction, erosions, ulcerations, or granulation tissue).1Efficacy in biologic/JAKi subgroupsSee how effective VELSIPITY was in  patients who were biologic/JAKi naive. EXPLORE SUBGROUPS LoadingReference:VELSIPITY (etrasimod) Summary of Product Characteristics. Brussels, Belgium: Pfizer Europe; February 2024.
Efficacy
PP-V1A-NLD-0012

Wilt u een bijwerking melden? Ga dan naar de 'Bijwerkingen melden' pagina en klik vervolgens op u van toepassing zijnde button.

PfizerPro AccountPfizerPro AccountU vindt informatie over geneesmiddelen, werkingsmechanismen, werkzame stoffen, doseringen en bijwerkingen die kunnen optreden. Zodat u nog beter in staat bent om uw patiënten te helpen.InloggenRegistrerenAccountUitloggen

De informatie die op deze website wordt aangeboden is uitsluitend bedoeld voor zorgverleners in Nederland. Bent u geen zorgverlener, maar patiënt of consument, ga dan naar www.pfizer.nl.

 

2025 Pfizer© Alle rechten voorbehouden.
 

PP-V1A-NLD-0012
U verlaat de website van Pfizer
Door op oké te klikken, verlaat u de website van Pfizer. De links naar websites buiten Pfizer worden u als service aangeboden. Pfizer heeft geen invloed op de inhoud van deze sites en is er niet voor verantwoordelijk.